MedTrace Logo

Nasal Antisepsis for C. Auris Prevention

NCT06282510 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-10-15

No results posted yet for this study

Summary

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Conditions

  • Candida Auris Infection
  • Colonization, Asymptomatic

Interventions

DRUG

Povidone Iodine Topical

Topical intranasal povidone iodine (10%) twice daily for 5 days

Sponsors & Collaborators

  • Rush University Medical Center

    collaborator OTHER

  • RML Specialty Hospital

    collaborator OTHER

  • Mary K Hayden

    lead OTHER

Principal Investigators

  • Mary K. Hayden, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2026-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06282510 on ClinicalTrials.gov